Compare PRSO & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRSO | NXL |
|---|---|---|
| Founded | 2008 | 2010 |
| Country | United States | United States |
| Employees | N/A | 7 |
| Industry | Semiconductors | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8M | 8.3M |
| IPO Year | 2000 | N/A |
| Metric | PRSO | NXL |
|---|---|---|
| Price | $1.06 | $0.46 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 549.9K | 362.7K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.23 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $14,573,000.00 | N/A |
| Revenue This Year | $18.48 | $15.52 |
| Revenue Next Year | $53.57 | $100.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.99 | N/A |
| 52 Week Low | $0.75 | $0.33 |
| 52 Week High | $2.37 | $2.00 |
| Indicator | PRSO | NXL |
|---|---|---|
| Relative Strength Index (RSI) | 49.91 | 53.14 |
| Support Level | $0.81 | $0.35 |
| Resistance Level | $1.05 | $0.46 |
| Average True Range (ATR) | 0.06 | 0.04 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 68.33 | 62.14 |
Peraso Inc is a fabless semiconductor company focused on the development and sale of: i) millimeter wavelength wireless technology, or mmWave, semiconductor devices and antenna modules based on its proprietary semiconductor devices and ii) performance of non-recurring engineering, or NRE, services and licensing of intellectual property, or IP. The company's primary focus is the development of mmWave, which is generally described as the frequency band from 24 Gigahertz, or GHz, to 300 GHz. Geographically the company generates revenue from the United States, Hong Kong, Taiwan, and the Rest of the World.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.